ClinicalTrials.gg
RecruitingNCT07714980Updated Nov 3, 2026

TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)

An interventional study of Transcutaneous Electrical Acupoint Stimulation and Sham Transcutaneous Electrical Acupoint Stimulation in Gastric Cancer (GC) and Stomach Neoplasms, sponsored by The Affiliated Hospital of Qingdao University. Recruiting at 13 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by The Affiliated Hospital of Qingdao University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 16, 2026Now RecruitingStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Stomach Neoplasms by The Affiliated Hospital of Qingdao University — 12 open to participants now, 14 under way, 1 of them phase 3. Stomach Neoplasms · The Affiliated Hospital of Qingdao University.

Planned enrollment
7th of 13
300 · median 300
Started
2026
with 2 others
No phase
12 of 16
9 open now
Primary completion
2028-07
later than 11 of 13 live
Registered
13th of 16
by date

Among the 16 studies in Stomach Neoplasms by The Affiliated Hospital of Qingdao University, this one is the 7th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2026, is one of 12 with no phase, reaches primary completion later than 11 of the 13 other live ones, and was the 13th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

12 of the 16 studies in Stomach Neoplasms by The Affiliated Hospital of Qingdao University are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Stomach Neoplasms by The Affiliated Hospital of Qingdao University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if transcutaneous electrical acupoint stimulation (TEAS) works to help people recover faster after laparoscopic surgery for stomach cancer. TEAS is a treatment that uses small electrical pulses through sticky pads on the skin. It does not use needles.

The main questions it aims to answer are:

Does TEAS help people pass gas (a sign that the digestive system is waking up) sooner after surgery?

Does TEAS help lower pain after surgery?

Does TEAS reduce the need for extra pain medication after surgery?

Researchers will compare three groups to see if TEAS works better when given before, during, and after surgery compared with only after surgery.

Group 1 receives TEAS before, during, and after surgery.

Group 2 receives a sham (inactive) treatment before and during surgery, and real TEAS after surgery.

Group 3 receives sham treatment at all time points.

All participants will receive the same standard pain relief and recovery care after surgery.

Participants will:

Be randomly assigned (like flipping a coin) to one of the three groups

Receive TEAS or sham treatment for 30 minutes before surgery, during surgery, and for 30 minutes each day on the first 3 days after surgery

Rate their pain on a 0-10 scale at 6, 12, 24, 48, and 72 hours after surgery

Complete quality-of-life questionnaires before surgery, on day 4 after surgery, and 30 days after surgery

Have a follow-up visit or phone call 30 days after leaving the hospital

This study includes 300 adults aged 18 to 80 years who are scheduled to have laparoscopic surgery for stomach cancer at 13 hospitals in Shandong Province, China.

Read the detailed description

This study is a prospective, multicenter, three-arm, parallel-group, randomized, sham-controlled trial conducted at 13 tertiary hospitals in Shandong Province, China. A total of 300 eligible participants scheduled for laparoscopic radical gastrectomy for stage I-III gastric cancer will be enrolled and randomly assigned in a 1:1:1 ratio to one of three groups: Peri-TEAS (transcutaneous electrical acupoint stimulation administered before, during, and after surgery), Post-TEAS (sham treatment before and during surgery, with real TEAS after surgery), or Sham-TEAS (sham treatment at all time points). Randomization will be performed using a centralized system with stratification by study center and a randomized block design with randomly assigned block sizes. Allocation concealment is ensured by the system, with group assignments revealed only after participant enrollment.

TEAS is delivered using a standardized electroacupuncture device (SDZ-V, Suzhou Medical Products Factory) with a dense-disperse wave (2 Hz alternating with 100 Hz, 5s/10s duty cycle) at individually titrated intensities. Four bilateral acupoints are selected: Hegu (LI4), Neiguan (PC6), Zusanli (ST36), and Shangjuxu (ST37), following WHO standard acupoint locations. For the Peri-TEAS group, stimulation begins 30 minutes before anesthesia induction at the individually determined maximal tolerable threshold, continues throughout surgery at the same intensity, and resumes postoperatively for 30 minutes daily on postoperative days 1 through 3. For the Post-TEAS group, sham stimulation is applied before and during surgery, with real TEAS administered postoperatively using the same protocol as the Peri-TEAS group. The Sham-TEAS group receives sham stimulation at all time points. To maintain blinding, the device screen is shielded, and operators use standardized scripts to avoid unblinding.

All participants receive a standardized enhanced recovery after surgery (ERAS) protocol, including no bowel preparation, preoperative carbohydrate loading, minimally invasive incisions, goal-directed fluid therapy, no routine nasogastric tubes, early removal of drains and urinary catheters (within 24 hours), early mobilization, and a stepwise enteral nutrition plan. Postoperative analgesia is provided via patient-controlled intravenous analgesia (PCIA) with sufentanil (2 μg/kg in 100 mL normal saline, background infusion 2 mL/h, bolus 2 mL, lockout 15 min), supplemented with flurbiprofen axetil 50 mg twice daily. Rescue analgesia (morphine 2-4 mg IV or equivalent) is administered for breakthrough pain (NRS ≥ 4), with all rescue doses converted to morphine equivalent dose for analysis.

The primary endpoint is time to first flatus after surgery. Key secondary endpoints include the area under the curve of movement-evoked pain NRS scores over 0-72 hours and total rescue analgesic consumption in morphine equivalent dose. Additional secondary endpoints encompass gastrointestinal recovery parameters (time to first bowel movement, tolerance of liquid/semi-liquid/solid diets), pain and analgesic use (resting pain AUC, time to first PCIA press, total PCIA presses, intraoperative propofol and remifentanil dosages), ambulation and recovery (time to first independent ambulation ≥5 meters, postoperative hospital stay meeting uniform discharge criteria), and safety outcomes (incidence and severity of nausea, vomiting, abdominal distension, postoperative complications graded by Clavien-Dindo classification, and 30-day readmission rate). Patient-reported outcomes are assessed using the EORTC QLQ-C30 and QLQ-STO22 questionnaires, and perioperative fatigue is evaluated using the ICFS-10, all administered preoperatively, on postoperative day 4, and at 30 days after surgery. Exploratory endpoints include inflammatory cytokines (CRP, IL-6, IL-1β, TNF-α), gastrointestinal hormones (motilin, gastrin, substance P, VIP, cholecystokinin), and immunoglobulins (IgA, IgG, IgM) measured from fasting blood samples on postoperative days 1, 3, and 5 (or at discharge if earlier).

Blinding is implemented for participants, surgeons, anesthesiologists, outcome assessors, and statisticians. TEAS operators are not blinded but are strictly prohibited from participating in any post-treatment clinical assessments or data collection. The success of blinding will be evaluated using Bang's Blinding Index. An independent Data Monitoring Committee, composed of one statistician and two external experts, will regularly review safety and compliance data.

Sample size calculation: Based on pilot data showing a mean difference of 8.22 hours in time to first flatus between Peri-TEAS and Post-TEAS (SD 18.36) and 15.35 hours between Peri-TEAS and Sham-TEAS (SD 25.74), with α = 0.05 (two-sided) and power = 80%, 80 participants per group are required. Accounting for a 20% dropout rate, the target enrollment is 300 participants (100 per group).

The statistical analysis will follow a fixed-sequence testing procedure to control the overall type I error at α = 0.05. Analyses will be performed on the full analysis set (intention-to-treat principle), with per-protocol analysis for sensitivity. All tests will be two-sided, with statistical significance set at P \< 0.05, using SAS 9.4.

The study protocol and informed consent form have been approved by the Ethics Committee of the Affiliated Hospital of Qingdao University and each participating center. The results will be disseminated through peer-reviewed academic journals.

03

Conditions studied

  • Gastric Cancer (GC)
  • Stomach Neoplasms

Browse trials for

Keywords

  • Gastric Cancer
  • Stomach Neoplasms
  • Transcutaneous Electrical Acupoint Stimulation
  • TEAS
  • Acupoint Stimulation
  • Randomized Controlled Trial
  • Postoperative Recovery
  • Pain Management
  • Gastrointestinal Function
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 80 years, both sexes
  • Endoscopically and radiographically confirmed resectable stage I-III gastric cancer (AJCC 8th edition)
  • Scheduled to undergo laparoscopic radical gastrectomy
  • Willing to sign the form and able to comply with all study procedures

Exclusion criteria

Exclusion Criteria:

  • (ASA) physical status ≥ IV
  • Clinical stage IV gastric cancer
  • Severe hepatic, renal, cardiovascular, or cerebrovascular diseases, or uncontrolled psychiatric disorders that may affect compliance or safety assessment
  • Participation in another clinical trial or receipt of any form of acupoint stimulation (acupuncture, electroacupuncture, TEAS, etc.) within 1 month prior to enrollment
  • Continuous use of opioids for more than 3 months prior to enrollment, with a daily dose ≥ 30 mg oral morphine equivalent
  • Implanted cardiac pacemaker or other electronic stimulation device, or skin infection/lesion at the stimulation site
  • Pregnancy or lactation
  • Emergency surgery due to bleeding, perforation, obstruction, etc.
  • Planned epidural anesthesia for the surgery
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Peri-TEAS Group

    Participants receive active transcutaneous electrical acupoint stimulation (TEAS) before, during, and after surgery. Stimulation begins 30 minutes before anesthesia induction, continues throughout the surgery, and is repeated for 30 minutes daily on postoperative days 1 through 3.

    Device: Transcutaneous Electrical Acupoint Stimulation

  • Experimental
    Post-TEAS Group

    Participants receive sham (inactive) TEAS before and during surgery, and active TEAS after surgery. Postoperative stimulation is given for 30 minutes daily on postoperative days 1 through 3.

    Device: Transcutaneous Electrical Acupoint Stimulation

  • Sham comparator
    Sham-TEAS Group

    Participants receive sham (inactive) TEAS at all time points: before surgery, during surgery, and after surgery (postoperative days 1 through 3, 30 minutes daily).

    Device: Sham Transcutaneous Electrical Acupoint Stimulation

Interventions

  • DeviceTranscutaneous Electrical Acupoint Stimulation

    Transcutaneous electrical acupoint stimulation (TEAS) using the Hwato SDZ-V electronic acupuncture device (Suzhou Medical Appliance Factory Co., Ltd., China). Four bilateral acupoints are stimulated: Hegu (LI4), Neiguan (PC6), Zusanli (ST36), and Shangjuxu (ST37), following WHO standard locations. Stimulation parameters: dense-disperse wave (2 Hz alternating with 100 Hz, 5s/10s duty cycle, pulse width 0.2 ms ± 30%). Intensity is individually titrated to the maximal tolerable threshold using a dual-threshold calibration method.

  • DeviceSham Transcutaneous Electrical Acupoint Stimulation

    Sham TEAS using the same Hwato SDZ-V device with identical appearance, indicator lights, and audible signals. The output leads are internally disconnected to deliver no electrical current. The operator performs the same procedural steps, including simulated dial adjustments, to maintain participant blinding.

06

What researchers measure

Primary outcomes

  1. Time to First Flatus After Surgery

    Time from the end of surgery to the patient's first self-reported passage of flatus. Patients and their families are instructed to record the exact time (to the nearest minute) immediately upon first flatus using a postoperative recovery diary card. Bedside nurses verify and collect the diary cards three times daily during rounds. Bowel movements induced by glycerin suppository or enema are excluded.

    Time frame: Measured from the end of surgery up to hospital discharge (expected up to 7 days postoperatively)

Secondary outcomes

  1. Area Under the Curve of Movement-Evoked Pain NRS Scores Over 0-72 Hours

    Area under the curve (AUC) of Numerical Rating Scale (NRS) scores for movement-evoked pain (MEP) from 0 to 72 hours postoperatively. NRS is a 11-point scale (0 = no pain, 10 = worst possible pain). Pain is assessed immediately after coughing using standardized instructions ("Please hold your wound with one hand, take a deep breath, and cough forcefully") at 6, 12, 24, 48, and 72 hours after surgery by a blinded assessor. If the patient cannot perform a standard cough, pain during turning in bed is assessed as a替代, with the reason recorded in the CRF. AUC is calculated using the trapezoidal rule. Pain during turning and ambulation are recorded simultaneously as exploratory analyses.

    Time frame: 0 to 72 hours postoperatively

  2. Total Rescue Analgesic Consumption in Morphine Equivalent Dose

    Total dose of all rescue analgesic medications administered for breakthrough pain (NRS ≥ 4) from PACU admission (T0) until discontinuation of PCIA and transition to oral analgesia, converted to morphine equivalent dose (mg MEDD) according to standard conversion factors: IV morphine 1 mg = 1 mg MEDD; IV hydromorphone 0.2 mg = 1 mg MEDD; IV tramadol 10 mg = 1 mg MEDD; oral oxycodone 1 mg = 1.5 mg MEDD. The date, time, and dose of each administration are captured concurrently from nursing medication records and the CRF.

    Time frame: From PACU admission (T0) until PCIA discontinuation (expected up to 72 hours postoperatively)

  3. Time to First Bowel Movement

    Time from the end of surgery to the first bowel movement, excluding those induced by glycerin suppository or enema.

    Time frame: Measured from the end of surgery up to hospital discharge (expected up to 7 days postoperatively)

  4. Time to First Tolerance of Liquid Diet

    Time from the end of surgery to first tolerance of a liquid diet, defined as the absence of vomiting or severe abdominal distension within 2 hours after ingestion.

    Time frame: Measured from the end of surgery up to hospital discharge (expected up to 7 days postoperatively)

  5. Time to First Tolerance of Semi-Liquid Diet

    Time from the end of surgery to first tolerance of a semi-liquid diet, defined as the absence of vomiting or severe abdominal distension within 2 hours after ingestion.

    Time frame: Measured from the end of surgery up to hospital discharge (expected up to 7 days postoperatively)

  6. Time to First Tolerance of Solid Diet

    Time from the end of surgery to first tolerance of a solid diet, defined as the absence of vomiting or severe abdominal distension within 2 hours after ingestion.

    Time frame: Measured from the end of surgery up to hospital discharge (expected up to 7 days postoperatively)

  7. Area Under the Curve of Resting Pain NRS Scores Over 0-72 Hours

    Area under the curve (AUC) of Numerical Rating Scale (NRS) scores for resting pain (PAR, Pain at Rest) from 0 to 72 hours postoperatively. NRS is a 11-point scale (0 = no pain, 10 = worst possible pain). Assessed by a blinded assessor at 6, 12, 24, 48, and 72 hours after surgery. AUC is calculated using the trapezoidal rule.

    Time frame: 0 to 72 hours postoperatively

  8. Time to First PCIA Pump Press

    Time from the end of surgery to the patient's first postoperative patient-controlled intravenous analgesia (PCIA) pump activation.

    Time frame: Measured from the end of surgery up to 48 hours postoperatively

  9. Total Number of PCIA Pump Presses Within 48 Hours Postoperatively

    Total number of patient-controlled intravenous analgesia (PCIA) pump presses (both effective and ineffective attempts) within the first 48 hours after surgery.

    Time frame: 0 to 48 hours postoperatively

  10. Intraoperative Propofol Dosage

    Total intraoperative propofol dosage (mg) administered during surgery, recorded by the anesthesiologist.

    Time frame: During surgery (intraoperative)

  11. Intraoperative Remifentanil Dosage

    Total intraoperative remifentanil dosage (μg) administered during surgery, recorded by the anesthesiologist.

    Time frame: During surgery (intraoperative)

  12. Time to First Independent Ambulation of ≥5 Meters

    Time from the end of surgery to the patient's first independent ambulation of at least 5 meters.

    Time frame: Measured from the end of surgery up to hospital discharge (expected up to 7 days postoperatively)

  13. Postoperative Hospital Stay

    Duration of postoperative hospital stay (hours), defined as meeting the uniform discharge criteria: tolerance of oral analgesia, tolerance of a semi-liquid diet, passage of flatus, and absence of uncontrolled complications.

    Time frame: From the end of surgery to hospital discharge (expected up to 7 days postoperatively)

  14. Incidence and Severity of Postoperative Nausea

    Incidence of postoperative nausea. Severity is assessed using the Numerical Rating Scale (NRS, 0 = no nausea, 10 = most severe nausea).

    Time frame: 0 to 72 hours postoperatively

  15. Incidence and Number of Episodes of Postoperative Vomiting

    Incidence and number of episodes of postoperative vomiting.

    Time frame: 0 to 72 hours postoperatively

  16. Rate of Rescue Antiemetic Use

    Rate of postoperative rescue antiemetic administration.

    Time frame: 0 to 72 hours postoperatively

  17. Incidence and Severity of Abdominal Distension

    Incidence of postoperative abdominal distension. Severity is assessed using the Numerical Rating Scale (NRS, 0 = no distension, 10 = most severe distension).

    Time frame: 0 to 72 hours postoperatively

  18. Incidence of Postoperative Complications

    Incidence of postoperative complications, graded by the Clavien-Dindo classification.

    Time frame: From the end of surgery up to 30 days post-discharge

  19. 30-Day Readmission Rate

    Rate of hospital readmission within 30 days after discharge.

    Time frame: 30 days after discharge

  20. Quality of Life - EORTC QLQ-C30

    Health-related quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The questionnaire assesses 15 dimensions of HRQoL, including physical, psychological, and social functions.

    Time frame: Preoperatively, on postoperative day 4, and at 30 days after surgery

  21. Quality of Life - EORTC QLQ-STO22

    Gastric cancer-specific quality of life assessed using the EORTC Quality of Life Questionnaire - Stomach Cancer Module (EORTC QLQ-STO22). The questionnaire includes five multi-item scales (dysphagia, pain, reflux, eating restrictions, anxiety) and four single items (dry mouth, body image, taste problems, hair loss). Higher scores indicate more severe symptoms.

    Time frame: Preoperatively, on postoperative day 4, and at 30 days after surgery

  22. Perioperative Fatigue - ICFS-10

    Perioperative fatigue assessed using the Identity-Consequence Fatigue Scale-10 (ICFS-10). The scale contains 10 items; a total score \> 24 indicates postoperative fatigue syndrome (POF).

    Time frame: Preoperatively, on postoperative day 4, and at 30 days after surgery

Other outcomes

  1. Inflammatory Cytokines - CRP, IL-6, IL-1β, TNF-α

    Serum levels of inflammatory cytokines, including C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α), measured from fasting blood samples to investigate whether TEAS exerts its effects through inhibition of systemic inflammation.

    Time frame: Postoperative days 1, 3, and 5 (or at discharge if earlier)

  2. Gastrointestinal Hormones - Motilin, Gastrin, Substance P, VIP, CCK

    Serum levels of gastrointestinal hormones, including motilin (MTL), gastrin (GAS), substance P (SP), vasoactive intestinal peptide (VIP), and cholecystokinin (CCK), measured from fasting blood samples.

    Time frame: Postoperative days 1, 3, and 5 (or at discharge if earlier)

  3. Immunoglobulins - IgA, IgG, IgM

    Serum levels of immunoglobulins, including IgA, IgG, and IgM, measured from fasting blood samples to explore whether TEAS attenuates postoperative immunosuppression.

    Time frame: Postoperative days 1, 3, and 5 (or at discharge if earlier)

07

Study locations

1 of 13 sites recruiting
  • Dongying People's Hospital
    Dongying, Shandong 257091, China
    Not yet recruiting
    • Hao Wang · Contact
  • Department of Gastrointestinal Surgery, Qingdao University Affiliated Hospital
    Qingdao, Shandong 266000, China
    Recruiting
  • Qingdao Municipal Hospital
    Qingdao, Shandong 266000, China
    Not yet recruiting
    • Hong Qi, MD · Contact
  • The Third People's Hospital of Qingdao
    Qingdao, Shandong 266041, China
    Not yet recruiting
    • Xiaolei Liu · Contact
  • Qingdao Central Hospital, University of Health and Rehabilitation Sciences
    Qingdao, Shandong 266042, China
    Not yet recruiting
    • Zhiwei Wang · Contact
  • Peking University People's Hospital Qingdao
    Qingdao, Shandong 266109, China
    Not yet recruiting
    • Deju Wang · Contact
  • Qingdao Chengyang District People's Hospital
    Qingdao, Shandong 266109, China
    Not yet recruiting
    • Baolian Song · Contact
  • The People's Hospital of Jimo, Qingdao
    Qingdao, Shandong 266200, China
    Not yet recruiting
    • Hongbo Wang · Contact
  • The People's Hospital of Rizhao
    Rizhao, Shandong 276826, China
    Not yet recruiting
    • Yang Yu · Contact
  • Weifang People's Hospital
    Weifang, Shandong 261041, China
    Not yet recruiting
    • Jianjun Qu · Contact
  • Weihai Municipal Hospital
    Weihai, Shandong 264200, China
    Not yet recruiting
    • Shaowei Sun · Contact
  • Weihai Central Hospital
    Weihai, Shandong 264400, China
    Not yet recruiting
    • Xinjian Wang · Contact
  • Yantai Yuhuangding Hospital
    Yantai, Shandong 264000, China
    Not yet recruiting
    • Jinchen Hu · Contact
08

References and documents

Publications

  • Pei L, Wang G, Yang S, Zhou S, Xu T, Zhou J, Zhang W, Lu K, Hu L, Wang Y, Wang K, You D, Wu Y, Li L, Guo J, Sun J. Electroacupuncture Reduces Duration of Postoperative Ileus After Laparoscopic Gastrectomy for Gastric Cancer: A Multicenter Randomized Trial. Gastroenterology. 2025 Jul;169(1):73-84. doi: 10.1053/j.gastro.2025.02.006. Epub 2025 Feb 18. PubMed 39978558 ↗
  • Zhou X, Cao SG, Tan XJ, Liu XD, Li ZQ, Kong LX, Tian YL, Liu D, Shen S, Sun YQ, Jiang HT, Zhou YB. Effects of Transcutaneous Electrical Acupoint Stimulation (TEAS) on Postoperative Recovery in Patients with Gastric Cancer: A Randomized Controlled Trial. Cancer Manag Res. 2021 Feb 12;13:1449-1458. doi: 10.2147/CMAR.S292325. eCollection 2021. PubMed 33603487 ↗
  • Tan SY, Jiang H, Ma Q, Ye X, Fu X, Ren YF, You FM. Effects of transcutaneous electrical acupoint stimulation on early postoperative pain and recovery: a comprehensive systematic review and meta-analysis of randomized controlled trials. Front Med (Lausanne). 2024 Apr 29;11:1302057. doi: 10.3389/fmed.2024.1302057. eCollection 2024. PubMed 38745738 ↗
  • Jiang T, Li J, Meng L, Wang J, Zhang H, Liu M. Effects of transcutaneous electrical acupoint stimulation on gastrointestinal dysfunction after gastrointestinal surgery: A meta-analysis. Complement Ther Med. 2023 May;73:102938. doi: 10.1016/j.ctim.2023.102938. Epub 2023 Feb 25. PubMed 36842636 ↗
  • Szmit M, Krajewski R, Rudnicki J, Agrawal S. Application and efficacy of transcutaneous electrical acupoint stimulation (TEAS) in clinical practice: A systematic review. Adv Clin Exp Med. 2023 Sep;32(9):1063-1074. doi: 10.17219/acem/159703. PubMed 37026972 ↗

Individual participant data

Plan to share: No — No plan for sharing individual participant data has been established for this investigator-initiated trial.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.

Of 358 non-industry interventional studies with no phase under Stomach Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 63. This study's planned 24 months is below that.

Counting every sponsor, half of 369 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Jul 20, 2026
StartActual
Jul 25, 2026
Primary completionEst.
Jul 2028
CompletionEst.
Aug 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 1, 2026
Sites
13 sites changed recruiting status (12 now not yet recruiting, 1 now recruiting)
Show 13 sites
  • Dongying People's Hospital · Dongying, Chinano status→Not yet recruiting
  • Department of Gastrointestinal Surgery, Qingdao University Affiliated Hospital · Qingdao, Chinano status→Recruiting
  • Qingdao Municipal Hospital · Qingdao, Chinano status→Not yet recruiting
  • The Third People's Hospital of Qingdao · Qingdao, Chinano status→Not yet recruiting
  • Qingdao Central Hospital, University of Health and Rehabilitation Sciences · Qingdao, Chinano status→Not yet recruiting
  • Peking University People's Hospital Qingdao · Qingdao, Chinano status→Not yet recruiting
  • Qingdao Chengyang District People's Hospital · Qingdao, Chinano status→Not yet recruiting
  • The People's Hospital of Jimo, Qingdao · Qingdao, Chinano status→Not yet recruiting
  • The People's Hospital of Rizhao · Rizhao, Chinano status→Not yet recruiting
  • Weifang People's Hospital · Weifang, Chinano status→Not yet recruiting
  • Weihai Municipal Hospital · Weihai, Chinano status→Not yet recruiting
  • Weihai Central Hospital · Weihai, Chinano status→Not yet recruiting
  • Yantai Yuhuangding Hospital · Yantai, Chinano status→Not yet recruiting
Oct 1, 2026
Start date
Jul 1, 2026→Jul 25, 2026
Oct 16, 2026
Show all 3 updates
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: identifiers
  2. Oct 16, 2026
    Start date Jul 1, 2026→Jul 25, 2026
    + 1 other change: verification date
  3. Oct 1, 2026
    Not yet recruiting→Recruiting
    13 sites changed recruiting status (12 now not yet recruiting, 1 now recruiting)
    Show 13 sites
    • Dongying People's Hospital · Dongying, Chinano status→Not yet recruiting
    • Department of Gastrointestinal Surgery, Qingdao University Affiliated Hospital · Qingdao, Chinano status→Recruiting
    • Qingdao Municipal Hospital · Qingdao, Chinano status→Not yet recruiting
    • The Third People's Hospital of Qingdao · Qingdao, Chinano status→Not yet recruiting
    • Qingdao Central Hospital, University of Health and Rehabilitation Sciences · Qingdao, Chinano status→Not yet recruiting
    • Peking University People's Hospital Qingdao · Qingdao, Chinano status→Not yet recruiting
    • Qingdao Chengyang District People's Hospital · Qingdao, Chinano status→Not yet recruiting
    • The People's Hospital of Jimo, Qingdao · Qingdao, Chinano status→Not yet recruiting
    • The People's Hospital of Rizhao · Rizhao, Chinano status→Not yet recruiting
    • Weifang People's Hospital · Weifang, Chinano status→Not yet recruiting
    • Weihai Municipal Hospital · Weihai, Chinano status→Not yet recruiting
    • Weihai Central Hospital · Weihai, Chinano status→Not yet recruiting
    • Yantai Yuhuangding Hospital · Yantai, Chinano status→Not yet recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07714980
Responsible party
Zhou Yanbing (Surgeon-in-Chief, Chief Physician, Professor of Surgery, The Affiliated Hospital of Qingdao University) — Principal investigator
First posted
Jul 20, 2026
Start date
Jul 25, 2026
Primary completion
Jul 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Yi Li, MD
Contact
zhanmusi8755@163.com
+86 186 6180 0210
Yanbing Zhou, MD
Contact
zhouyanbing999@aliyun.com
+86 137 0897 1773
Yanbing Zhou
study chair · The Affiliated Hospital of Qingdao University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion